Angiocrine Bioscience Announces Poster Presentation of AB-205 Trial during the 64th Annual Meeting of the American Society of Hematology (ASH)

/PRNewswire/ -- Angiocrine Bioscience, Inc., a clinical-stage biopharmaceutical company today announced that it has been selected by the American Society of...

Related Keywords

United States ,American ,Paul Finnegan ,Michael Scordo ,American Society Of Hematology ,Prnewswire Angiocrine Bioscience Inc ,National Institute Of Health Clinicaltrials ,Epidemiological Program ,Drug Administration ,Angiocrine Bioscience Inc ,Ernestn Morial Convention Center ,American Society ,Regenerative Medicine Advanced Therapy ,Orphan Drug ,Convention Center ,Placebo Controlled Study ,Versus Placebo Plus Standard ,Lymphoma Undergoing High Dose Therapy ,Autologous Hematopoietic Cell Transplantation ,National Institute ,Severe Toxicities ,Autologous Hematopoietic Cell Transplant ,Angiocrine Bioscience ,Advanced Reparative Medicines ,Nc ,Health Care Amp Hospitals ,Medical Pharmaceuticals ,Biotechnology ,Pharmaceuticals ,Clinical Trials Amp Medical Discoveries ,Trade Show News ,